Research programme: stimulator of interferon genes antagonists - F-star Therapeutics
Alternative Names: SB 36; Stimulator of interferon genes antagonists - F-star Therapeutics; STING antagonist R&D program - F-star Therapeutics; STING antagonists - F-star TherapeuticsLatest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator Spring Bank Pharmaceuticals
- Developer F-star Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action STING1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma